The NASCAR Deal Everyone Is Reading Wrong

When Rocket Doctor AI (CSE: AIDR | OTC: AIRDF | FSE: 939) announced a marketing partnership with Rick Ware Racing and FinTekk AP in June, the reaction split into two camps, and both were lazy.

Camp one: a sub-$50M micro-cap is buying NASCAR sponsorship instead of hiring doctors.Camp two: national TV exposure, millions of eyeballs, this is the catalyst.

Neither camp read the agreement. I did. The interesting part isn’t the racing; it’s the consideration structure, and it deserves more scrutiny than either the bulls or the bears have given it.

What was actually signed

Per the June 8, 2026 press release, the definitive Marketing Agreement is dated effective June 5, 2026, between Rocket Doctor AI, Rick Ware Racing, LLC, and FINTEKK AP, LLC.

The terms, stated plainly:

Phase one (June 6 – September 30, 2026): 7,000,000 common shares at a deemed price of USD $0.50, a stated value of USD $3,500,000. Issued in equal monthly installments beginning July 6, 2026, as services are rendered.

Phase two (auto-continuing): Unless the Company delivers written notice at least ten days before September 30, 2026, electing to pause, services continue through December 31, 2026 for an additional 3,000,000 shares at the same deemed $0.50, USD $1,500,000. Split 1.5M on November 6 and 1.5M on December 6.

The 2027 option: The Marketing Partners hold an option, exercisable on mutual written consent, to receive an additional USD $5,000,000 in Company Shares at the greater of $0.50 or a 10% premium to market, for renewal of substantially similar services in calendar 2027.

Lock-up: Every tranche carries a twelve-month contractual lock-up from its issuance date.

Relationship: Arms’ length. No finders’ fees.

The correction I want to make loudly

Several aggregators, including at least one AI-generated summary that has been circulating, have described the US$5 million as a potential future investment into Rocket Doctor AI to support U.S. expansion.

That is backwards. Read the clause. The Marketing Partners have an option to receive$5,000,000 in Company Shares as consideration for renewing their services in 2027. That is money flowing out, not in. It is a renewal price tag, not a funding commitment.

If you have seen that framing repeated and believed it, correct it now. It changes the deal's entire arithmetic.

So what does this actually cost

Ten million shares across 2026 against roughly 96.9 million outstanding as of the Q1 MD&A date. Call it just under 10% dilution on a post-issuance basis for a seven-month brand campaign. If the 2027 option is exercised at the $0.50 floor, that’s another ~10 million shares.

Two honest observations about that:

It preserves cash, which matters. For a company where the binding constraint is physician credentialing throughput and where the balance sheet just took on a c. C$3.1M convertible debenture at 12% (closed August 6, 2026), not writing a $3.5M cheque is a real advantage. Stock-settled marketing is dilution, but it is dilution you choose rather than debt you service.

The deemed price is doing work. A $0.50 USD floor sets a ceiling on share count. If the market price sits below that deemed price when tranches issue, existing shareholders are paying fewer shares than a market-priced deal would require. If it sits well above, the partners are getting a discount. Which way that cuts depends entirely on where the stock trades through the issuance calendar, and the twelve-month lock-up means those shares don’t hit the float until mid-2027 at the earliest.

That last point matters more than the sponsorship itself. Ten million locked shares stacked on top of the December 2026 escrow tranche and the January 22, 2027 warrant expiry is a supply calendar worth mapping.

Now, the Biohaven precedent

Here is where it gets genuinely interesting, and where I want to be very careful not to sell you something I can’t support.

The No. 51 Rick Ware Racing car is not new to healthcare branding.

On December 2, 2020, Biohaven Pharmaceuticals (then NYSE: BHVN) announced that Nurtec ODT (rimegepant), its migraine treatment, would be the primary partner on the No. 51 RWR entry for the entire 2021 NASCAR Cup Series, debuting at the Daytona 500. The program expanded to the No. 51 IndyCar entry in May 2021 and renewed for a second full season across both series in January 2022.

The driver was Cody Ware, the same driver on the Rocket Doctor AI car, and Cody lives with migraine himself. Rick Ware initially connected with Biohaven’s CEO because his own family members suffer from migraines.

Alongside the racing, Biohaven and RWR ran a Military Salutes Program: thirty-five military base visits across 2021, over 1,200 service members honoured, and more than $150,000 donated to service member and first responder charities.

In May 2022, Pfizer announced it would acquire Biohaven for approximately $11.6 billion. The deal closed October 3, 2022, at $148.50 per share in cash, with Biohaven simultaneously spinning off its non-CGRP pipeline into a new listed entity.

Roughly twenty-two months from first green flag to closed acquisition.

What that precedent legitimately establishes

The platform can credibly carry a healthcare brand. This is nothing. Regulated healthcare marketing is hard; a pharmaceutical company with an FDA-approved drug and an army of compliance lawyers signed off on putting a prescription migraine therapy on a Cup Series car and kept it there for two full seasons. That is a real reference point, and it is the strongest argument for the format.

The audience overlap is real. Biohaven’s thesis was that NASCAR reaches rural, working-class, military-adjacent populations with chronic conditions and inconsistent access to care. That's nearly identical to Rocket Doctor’s stated core patient population: rural, underserved, working-class, Medicaid and Medicare. Cody Ware said as much in the Rocket Doctor release, and Biohaven’s team said the same thing five years earlier.

Rick Ware Racing has done this before. They are not learning healthcare activation on Rocket Doctor’s dime.

What that precedent absolutely does not establish

One. Pfizer did not buy a brand. It bought a molecule. Pfizer had already signed a strategic collaboration with Biohaven in November 2021 to commercialize rimegepant and zavegepant outside the U.S., $500 million paid at closing in January 2022, including a $350 million equity investment. The acquirer was already inside the company as a partner and shareholder before the takeout. That is the actual causal chain: a commercial partner exercising an option it had effectively already priced. NASCAR was a line item.

Two. The scale gap is enormous. Biohaven was a commercial-stage NYSE company with an FDA-approved drug generating hundreds of millions in revenue, running celebrity DTC campaigns in parallel. Nurtec crossed $928 million in 2023 sales under Pfizer. Rocket Doctor AI is a micro-cap paying its marketing partners in stock. The reused template doesn't make the outcomes comparable, and pretending otherwise is a category error.

So while I am not saying a deal with Cody or FINTEKK means Rocket Doctor AI will be acquired or re-rate to 30X+ over the next couple of years. I am saying that this partnership is extremely accretive to Rocket Doctor AI and all of its stakeholders.

The actual investable question

Strip out the acquisition fantasy and the honest version of this thesis is narrower and more testable.

Rocket Doctor’s binding constraint is not awareness. It is credentialed physician supply. The company went from roughly 12 clinically active U.S. MDs in April 2026 to 22 active with 33 in credentialing. Patient visits moved from under 100 per month in December 2025 to over 1,000 per month by April 2026. That growth is a supply-side story, not a demand-side one.

So the question is: does a national brand campaign relieve a supply constraint?

It plausibly can, through two channels neither the bulls nor bears talk about much:

Physician recruitment. A doctor deciding whether to build a practice on an unfamiliar platform weighs institutional credibility. A brand visible on NBC and FOX is not a clinical credential, but it is a legitimacy signal, and physician acquisition is the actual bottleneck.

B2B and payer conversations. Health plan business development is a relationship business where being a known name shortens the sales cycle. The campaign’s stated geographic emphasis, California, New York and the Tri-State area, Texas, Florida, maps onto both existing payer geographies and expansion targets.

The weaker channel is the one the press release leads with: direct patient acquisition. National broadcast reaches all fifty states. Rocket Doctor can only see patients where it has credentialed physicians and in-network payer contracts, currently California, New York, and Maryland. A viewer in Ohio who sees the car and searches the platform is a wasted impression. That geographic mismatch is the strongest bear point on this deal, and management has not addressed it directly.

Named risks

• Dilution is real and front-loaded. Roughly 10% in 2026, potentially another 10% in 2027 if the option is exercised. This is not a free deal because no cash moved.
• Auto-renewal is opt-out, not opt-in. Phase two continues by default unless the Company affirmatively elects to pause ten days before September 30, 2026. Watch for that decision; silence is a decision.
• The 2027 option converts a marketing partner into a large holder. Twenty million cumulative shares under lock-up create a future supply overhang with a known unlock schedule.
• Attribution will be difficult. Brand campaigns are hard to measure. If Q3 and Q4 physician credentialing and visit volumes do not inflect, the company will have spent 10% of the equity on something it cannot demonstrate worked.

Five takeaways

1. The $5 million is an outflow, not an inflow. Correct this wherever you see it. The Marketing Partners have an option to receive $5M in shares for 2027 renewal services.
2. The real cost is ~10% dilution in 2026 at a deemed $0.50 USD, all under a twelve-month lock-up, landing in the same window as the December escrow tranche and the January 2027 warrant expiry.
3. The Biohaven precedent is real and useful, as proof the platform works for healthcare brands. Same team, same car number, same driver, two full seasons, a compliance-heavy pharmaceutical sponsor.
4. The Biohaven acquisition is not a roadmap. Pfizer bought a CGRP franchise it was already partnered on. The sponsorship was incidental. Anyone selling you “sponsored, then acquired” is selling correlation.
5. The thesis validation metric has not changed. It is credentialing conversion and per-physician visit volume, not impressions, not followers, not broadcast reach. If Q3 numbers show credentialing accelerating, the campaign has a case. If they don’t, this was an expensive paint job.

I hold over 1.5 million shares of Rocket Doctor AI ($AIDR / $AIRDF / FSE: 939), accumulated over time, representing a meaningful portion of my portfolio. I have no relationship with Rocket Doctor AI, Rick Ware Racing, or FinTekk AP, and I am not compensated for this content. Figures cited are drawn from the Company’s June 8, 2026 press release, the Q1 2026 MD&A and interim financial statements filed on SEDAR+, and publicly available sources on Biohaven Pharmaceuticals and its acquisition by Pfizer. Analyst coverage referenced elsewhere in my work carries disclosed conflicts: Maxim Group makes a market in the security; Fundamental Research Corp is paid for coverage.

NFA. DYOR.